APA (7th ed.) Citation

Corboy, J. R., Fox, R. J., Kister, I., Cutter, G. R., Morgan, C. J., Seale, R., . . . Bowen, J. (2023). Risk of new disease activity in patients with multiple sclerosis who continue or discontinue disease-modifying therapies (DISCOMS): A multicentre, randomised, single-blind, phase 4, non-inferiority trial. Lancet neurology, 22(7), 568-577. https://doi.org/10.1016/S1474-4422(23)00154-0

Chicago Style (17th ed.) Citation

Corboy, John R., et al. "Risk of New Disease Activity in Patients with Multiple Sclerosis Who Continue or Discontinue Disease-modifying Therapies (DISCOMS): A Multicentre, Randomised, Single-blind, Phase 4, Non-inferiority Trial." Lancet Neurology 22, no. 7 (2023): 568-577. https://doi.org/10.1016/S1474-4422(23)00154-0.

MLA (9th ed.) Citation

Corboy, John R., et al. "Risk of New Disease Activity in Patients with Multiple Sclerosis Who Continue or Discontinue Disease-modifying Therapies (DISCOMS): A Multicentre, Randomised, Single-blind, Phase 4, Non-inferiority Trial." Lancet Neurology, vol. 22, no. 7, 2023, pp. 568-577, https://doi.org/10.1016/S1474-4422(23)00154-0.